These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 29987143)

  • 41. Trypanosoma cruzi benznidazole susceptibility in vitro does not predict the therapeutic outcome of human Chagas disease.
    Moreno M; D'ávila DA; Silva MN; Galvão LM; Macedo AM; Chiari E; Gontijo ED; Zingales B
    Mem Inst Oswaldo Cruz; 2010 Nov; 105(7):918-24. PubMed ID: 21120364
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Sesquiterpene lactone potentiates the immunomodulatory, antiparasitic and cardioprotective effects on anti-Trypanosoma cruzi specific chemotherapy.
    Gonçalves-Santos E; Vilas-Boas DF; Diniz LF; Veloso MP; Mazzeti AL; Rodrigues MR; Oliveira CM; Fernandes VHC; Novaes RD; Chagas-Paula DA; Caldas IS
    Int Immunopharmacol; 2019 Dec; 77():105961. PubMed ID: 31685438
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The repositioned drugs disulfiram/diethyldithiocarbamate combined to benznidazole: Searching for Chagas disease selective therapy, preventing toxicity and drug resistance.
    Almeida-Silva J; Menezes DS; Fernandes JMP; Almeida MC; Vasco-Dos-Santos DR; Saraiva RM; Viçosa AL; Perez SAC; Andrade SG; Suarez-Fontes AM; Vannier-Santos MA
    Front Cell Infect Microbiol; 2022; 12():926699. PubMed ID: 35967878
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Combination Therapy Using Benznidazole and Aspirin during the Acute Phase of Experimental Chagas Disease Prevents Cardiovascular Dysfunction and Decreases Typical Cardiac Lesions in the Chronic Phase.
    Pereira RS; Malvezi AD; Lovo-Martins MI; Lucchetti BFC; Santos JP; Tavares ER; Verri WA; de Almeida Araújo EJ; Yamauchi LM; Yamada-Ogatta SF; Martins-Pinge MC; Pinge-Filho P
    Antimicrob Agents Chemother; 2020 Jun; 64(7):. PubMed ID: 32366719
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Trypanosoma cruzi: effect of benznidazole therapy combined with the iron chelator desferrioxamine in infected mice.
    Francisco AF; de Abreu Vieira PM; Arantes JM; Pedrosa ML; Martins HR; Silva M; Veloso VM; de Lana M; Bahia MT; Tafuri WL; Carneiro CM
    Exp Parasitol; 2008 Dec; 120(4):314-9. PubMed ID: 18789321
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The immunomodulatory effects of the Enalapril in combination with Benznidazole during acute and chronic phases of the experimental infection with Trypanosoma cruzi.
    Leite ALJ; Paula Costa G; Lopes LR; Reis Mota LWD; Vieira PMA; Talvani A
    Acta Trop; 2017 Oct; 174():136-145. PubMed ID: 28720491
    [TBL] [Abstract][Full Text] [Related]  

  • 47. 4-nitrobenzoylcoumarin potentiates the antiparasitic, anti-inflammatory and cardioprotective effects of benznidazole in a murine model of acute Trypanosoma cruzi infection.
    Vilas-Boas DF; Oliveira RRG; Gonçalves-Santos E; Silva LS; Diniz LF; Mazzeti AL; Brancaglion GA; Carvalho DT; Caldas S; Novaes RD; Caldas IS
    Acta Trop; 2022 Apr; 228():106314. PubMed ID: 35038424
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Benznidazole alters the pattern of Cyclophosphamide-induced reactivation in experimental Trypanosoma cruzi-dependent lineage infection.
    Santos DM; Martins TA; Caldas IS; Diniz LF; Machado-Coelho GL; Carneiro CM; Oliveira Rde P; Talvani A; Lana M; Bahia MT
    Acta Trop; 2010 Feb; 113(2):134-8. PubMed ID: 19854145
    [TBL] [Abstract][Full Text] [Related]  

  • 49. An in vitro iron superoxide dismutase inhibitor decreases the parasitemia levels of Trypanosoma cruzi in BALB/c mouse model during acute phase.
    Olmo F; Urbanová K; Rosales MJ; Martín-Escolano R; Sánchez-Moreno M; Marín C
    Int J Parasitol Drugs Drug Resist; 2015 Dec; 5(3):110-6. PubMed ID: 26236582
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Activity profile of two 5-nitroindazole derivatives over the moderately drug-resistant
    Fonseca-Berzal C; da Silva CF; Batista DDGJ; de Oliveira GM; Cumella J; Batista MM; Peres RB; Silva da Gama Nefertiti A; Escario JA; Gómez-Barrio A; Arán VJ; Soeiro MNC
    Parasitology; 2020 Sep; 147(11):1216-1228. PubMed ID: 32530391
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Nitrotriazole-Based Compounds as Antichagasic Agents in a Long-Treatment
    Papadopoulou MV; Bloomer WD; Rosenzweig HS; Mazzeti AL; Gonçalves KR; Mendes PF; Bahia MT
    Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28242662
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Treatment with benznidazole and pentoxifylline regulates microRNA transcriptomic profile in a murine model of Chagas chronic cardiomyopathy.
    Silva Grijó Farani P; Iandra da Silva Ferreira B; Begum K; Vilar-Pereira G; Pereira IR; Fernández-Figueroa EA; Cardenas-Ovando RA; Almeida IC; Roy S; Lannes-Vieira J; Moreira OC
    PLoS Negl Trop Dis; 2023 Mar; 17(3):e0011223. PubMed ID: 36972298
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Different Therapeutic Outcomes of Benznidazole and VNI Treatments in Different Genders in Mouse Experimental Models of Trypanosoma cruzi Infection.
    Guedes-da-Silva FH; Batista DG; da Silva CF; Meuser MB; Simões-Silva MR; de Araújo JS; Ferreira CG; Moreira OC; Britto C; Lepesheva GI; Soeiro Mde N
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7564-70. PubMed ID: 26416857
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Combination Chemotherapy with Suboptimal Doses of Benznidazole and Pentoxifylline Sustains Partial Reversion of Experimental Chagas' Heart Disease.
    Vilar-Pereira G; Resende Pereira I; de Souza Ruivo LA; Cruz Moreira O; da Silva AA; Britto C; Lannes-Vieira J
    Antimicrob Agents Chemother; 2016 Jul; 60(7):4297-309. PubMed ID: 27161638
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Benznidazole and Posaconazole in Eliminating Parasites in Asymptomatic T. Cruzi Carriers: The STOP-CHAGAS Trial.
    Morillo CA; Waskin H; Sosa-Estani S; Del Carmen Bangher M; Cuneo C; Milesi R; Mallagray M; Apt W; Beloscar J; Gascon J; Molina I; Echeverria LE; Colombo H; Perez-Molina JA; Wyss F; Meeks B; Bonilla LR; Gao P; Wei B; McCarthy M; Yusuf S;
    J Am Coll Cardiol; 2017 Feb; 69(8):939-947. PubMed ID: 28231946
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clomipramine and benznidazole association for the treatment of acute experimental Trypanosoma cruzi infection.
    Strauss M; Lo Presti MS; Bazán PC; Baez A; Fauro R; Esteves B; Sanchez Negrete O; Cremonezzi D; Paglini-Oliva PA; Rivarola HW
    Parasitol Int; 2013 Jun; 62(3):293-9. PubMed ID: 23500720
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Benznidazole modulates release of inflammatory mediators by cardiac spheroids infected with Trypanosoma cruzi.
    de Almeida Fiuza LF; Batista DDGJ; Nunes DF; Moreira OC; Cascabulho C; Soeiro MNC
    Exp Parasitol; 2021 Feb; 221():108061. PubMed ID: 33383023
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Outcome of E1224-Benznidazole Combination Treatment for Infection with a Multidrug-Resistant Trypanosoma cruzi Strain in Mice.
    Diniz LF; Mazzeti AL; Caldas IS; Ribeiro I; Bahia MT
    Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29555633
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Organometallic Gold(III) Complex [Au(Hdamp)(L1
    Lopes CD; Possato B; Gaspari APS; Oliveira RJ; Abram U; Almeida JPA; Rocho FDR; Leitão A; Montanari CA; Maia PIS; da Silva JS; de Albuquerque S; Carneiro ZA
    ACS Infect Dis; 2019 Oct; 5(10):1698-1707. PubMed ID: 31419384
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Changes of RAPD profile of Trypanosoma cruzi II with Canova and Benznidazole.
    Aleixo DL; Ferraz FN; de Melo CS; Gomes ML; Toledo MJ; Kaneshima EN; Bersani-Amado CA; Araújo SM
    Homeopathy; 2008 Apr; 97(2):59-64. PubMed ID: 18439965
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.